Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Physicians who Treat ADHD (US)

Council Members in this Study Group: 459

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Daniel Wynn, MD, Director of Clinical Research, CONSULTANTS IN NEUROLOGY LTDDaniel Wynn, MD

Director of Clinical Research
CONSULTANTS IN NEUROLOGY LTD
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke,chronic...

Marina Raikhel, MD, Director, TORRANCE MEMORIAL MEDICAL CENTERMarina Raikhel, MD

Director
TORRANCE MEMORIAL MEDICAL CENTER
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Marina Raikhel, MD, is an active family practitioner with a particular interest in primary care and ob/gyn focus. She has expertise in the treatment of a wide variety of internal medicine conditions, with special focus on diabetes, hypertension, obesity, anxiety, and depression. She is Director ofTorrance...

David Zimmerman, PharmD

President/Owner
Doctors of Pharmacy, Inc.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30 years of experience, specializing in pharmacyservices...

David Rosenberg, MD

Chief of Psychiatry and Psychology
CHILDREN'S HOSPITAL OF MICHIGAN
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

David Rosenberg, MD, is a tenured Professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg has authored first ever textbook on pediatric...

Amit Vijapura, MD, Owner, AMIT VIJAPURA MDAmit Vijapura, MD

Owner
AMIT VIJAPURA MD
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Amit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also...

Robert Schulte

Psychiatrist
North Scottsdale Psychiatric Specialists
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Robert Schulte, MD, is a Private Practitioner and a Psychiatrist at North Scottsdale Psychiatric Specialists in Arizona. He is board certified in Adult Psychiatry and Child and Adolescent Psychiatry with extensive experience with children and adult's re-psychotherapy and psychopharmacology and thetreatment...

Rami Kaminski, MD

Founder and Director
Institute for Integrative Psychiatry
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Rami Kaminski, MD, is Director and Founder of the Institute for Integrative Psychiatry in New York, a not-for-profit organization aimed at evaluating current psychiatric services and how they integrate with medicine, such as the mutual effects between medical and psychiatric conditions. Prior to that,...

Lawrence Ginsberg, MD

President
RED OAK PSYCHIATRY ASSOCIATES, P. A.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

Lurasidone will be an important new option for the treatment of Schizophrenia

August 29, 2009

LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY | www.pipelinereview.com

 After much disappointment over the current Atypical Antipsychotics , Lurasidone shows great promise for treatment refractory Schizophrenics.

New Treatment Option for the Hearing Impaired

August 22, 2009

Oticon Medical Receives FDA Clearance To Market Innovative Bone Anchored Hearing System | www.medicalnewstoday.com

 Oticon's new bone anchored hearing implant might offer unique advantages to the hearing impaired.

Treatment of Social Anxiety Disorderved

August 6, 2009

NeuroSearch successfully advances NSD-721 for treatment of social anxiety disorder and receives EUR 5 million in equity financing under the alliance with GlaxoSmithKline | www.pipelinereview.com

 NeuroSearch new drug NSD-721 will be of great benefit to patients with Social Anxiety Disorder.

Is this the end of Bifeprunoxyndrome.

August 3, 2009

Lundbeck, Solvay discontinue all joint R&D activities for bifeprunox to treat schizophrenia | www.pharmabiz.com

 Bifeprunox initially looked like it might be a blockbuster for Solvoy when it was first studied.

Sex - we can chemically get it up and now last longer?

August 2, 2009

Sciele Pharma And Plethora Solutions Announce Positive Results Of Final Phase III Pivotal Trial For PSD502 For Premature Ejaculation | www.medicalnewstoday.com

?? breakthrough

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Other Freestanding Healthcare Facility
  • Academic Institution*
  • Government/Military Hospital or Clinic

Members in this Study Group often have these job titles:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Director
  • Medical Director
  • President